Nationwide study of COVID-19 outcomes in hematologic patients following bone marrow transplantation

Area of Science:

• Hematology
• Infectious Diseases
• Transplantation Immunology

Background:

• Patients with hematological malignancies (HMs) face increased risks from immunosuppression, particularly after hematopoietic stem cell transplantation (HSCT).
• The COVID-19 pandemic amplified these risks, yet specific data on HSCT recipients remained limited.
• Understanding COVID-19's impact on HSCT patients is crucial for managing this vulnerable population.

Purpose of the Study:

• To investigate the clinical and demographic profiles of HSCT recipients hospitalized with COVID-19 in Spain.
• To identify factors associated with in-hospital mortality among HSCT patients with COVID-19.
• To compare outcomes between HSCT recipients and non-recipients with COVID-19.

Main Methods:

• A nationwide, retrospective analysis of hospitalized HM patients with COVID-19 in Spain (2020-2022).
• Inclusion of 35,648 HM patients, with a subgroup of 2,324 (6.5%) who had undergone HSCT.
• Statistical analyses included descriptive statistics, multivariate logistic regression, and survival analyses to determine mortality predictors.

Main Results:

• The in-hospital mortality rate for HSCT recipients was 13%, significantly lower than the 20% observed in non-HSCT patients.
• Factors associated with increased mortality in HSCT recipients included older age, dementia, acute leukemia, and solid tumors.
• Despite immunosuppression, HSCT recipients demonstrated relatively favorable COVID-19 outcomes, suggesting partial immune reconstitution.

Conclusions:

• HSCT recipients with COVID-19 exhibit distinct clinical characteristics and mortality risks compared to non-recipients.
• These findings underscore the necessity for specialized management protocols for HSCT patients during the COVID-19 pandemic.
• Further research into immunological recovery and transplant-specific factors influencing COVID-19 outcomes is warranted.